Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1359 in Healthy Volunteers

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy

In brief

The purpose of this study is to evaluate safety and pharmacokinetics of single ascending IV doses of GMI-1359 in healthy adult subjects.

Key facts

Study ID

NCT02931214

Run by

GlycoMimetics Incorporated

People needed

58

Starts

2016-08-01

Expected to finish

2018-11-01

Last updated by the study team

2019-03-04

Who can join

Age: 19 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy adult male or females, 19-60 years of age (inclusive).
• Medically healthy with no clinically significant screening results.
• Females of childbearing potential must either be sexually inactive (abstinent) for 3 months prior to dosing or be using an acceptable birth control method
• Females must have a negative pregnancy test at the time of screening and prior to dosing for inclusion in the study.
• Understands the study procedures in the informed consent form, and be willing and able to comply with the protocol.

You may not qualify if…

• Subject is mentally or legally incapacitated.
• History of any illness that, in the opinion of the PI, might confound the results of the study or poses an additional risk to the subjects by their participation in the study.
• Normal clinical laboratory values.
• Normal heart rate and blood pressure.
• Blood donation or significant blood loss within 56 days prior to dosing.
• Plasma donation within 7 days prior to dosing.
• Participation in another clinical trial within 28 days prior to dosing.

Where it is running

• Celerion — Lincoln, Nebraska, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.